Rotavirus Infections Clinical Trial
Official title:
Nested Case-control Analysis of the Influence of the Microbiome on Rotavirus Vaccine Immunogenic Response in Infants in Karachi, Pakistan
This is a proposal for a nested case‐control study within an ongoing rotavirus vaccine immunogenicity clinical trial Karachi, Pakistan. The primary study aim is to compare the fecal microbiota composition and diversity of infants who do (control) and do not (case) demonstrate immune seroconversion to rotavirus vaccination. The infants will be matched for vaccination dose, age and breast‐feeding practices.
Status | Completed |
Enrollment | 76 |
Est. completion date | November 2013 |
Est. primary completion date | November 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - 6 weeks 0 days to 7 weeks 6 days age at the time of enrollment. - Healthy infant free of chronic or serious medical condition as determined by history and physical exam at time of enrollment into in the study. - Written informed consent obtained from the parents or guardians. - Availability of baseline fecal sample collected before Rotarix vaccination - Written informed consent obtained from the parents or guardians for nested study Exclusion Criteria: - Hypersensitivity to any of the vaccine components - Use of any investigational drug or vaccine other than the study vaccine within 30 days of first dose of study vaccine or during the study. - Use of any immunosuppressive drugs. - Previous intussusceptions or abdominal surgery. - Enrollment in any other trial (besides NCT01199874). - Birth weight less than 1500 grams; or if birth weight is unknown, weight less than 2000 grams on or before 28 days. - Immunoglobulin and/or blood products use since birth or during the study period. Nested study additional exclusion criteria: - Positive serum anti-rotavirus Immunoglobulin A (> 20 U/ml) at 6 weeks of age, indicative of prior rotavirus infection |
Observational Model: Case Control, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Aga Khan University, Centers for Disease Control and Prevention, University of Padua, Wageningen University and Research Centre |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | microbiome diversity (Shannon's index) and composition (relative abundance) | Microbiota composition will be measured by calculating and comparing a % of the phylogenetic groups present in both groups Diversity will be measured by calculating a comparing a Shannon's reciprocal index of diversity, 1/D in both groups The relative abundance of microbial groups will be measured by calculating and comparing the ribosomal ribonucleic acid gene copy per gram of feces over time in both groups |
at 6 weeks of age, pre-rotavirus vaccination | No |
Secondary | microbiome diversity (Shannon's index) and composition (relative abundance) | Microbiota composition post vaccination will be measured by calculating and comparing a % of the phylogenetic groups present in both groups Diversity post vaccination will be measured by calculating a comparing a Shannon's reciprocal index of diversity, 1/D in both groups The relative abundance of microbial groups post vaccination will be measured by calculating and comparing the ribosomal ribonucleic acid gene copy per gram of feces over time in both groups |
at 1 to 3 years of age post-rotavirus vaccination | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02538211 -
The Role of the Intestinal Microbiome in Enteric and Systemic Vaccine Immune Responses
|
N/A | |
Withdrawn |
NCT00757926 -
Safety and Immunogenicity Study of the Recombinant Human Bovine Reassortant Rotavirus Vaccine in Healthy Indian Infants
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT00484952 -
Surveillance of Hospitalizations Due to Rotavirus Infections Among Children From Israel
|
N/A | |
Completed |
NCT00092443 -
Dose Confirmation Efficacy Study (V260-007)
|
Phase 3 | |
Terminated |
NCT01357174 -
ROTATEQ™ Post-Marketing Surveillance in the Philippines
|
N/A | |
Recruiting |
NCT01363726 -
Surveillance of Rotavirus Gastroenteritis in Children <5 Years
|
N/A | |
Completed |
NCT00130832 -
Concomitant Use and Staggered Use of Vaccine and Oral Poliovirus (OPV) in Healthy Infants (V260-014)(COMPLETED)
|
Phase 3 | |
Recruiting |
NCT06080906 -
Phase II Clinical Trial of the Inactivated Rotavirus Vaccine
|
Phase 2 | |
Recruiting |
NCT03313128 -
SaniVac Trial - Sanitation and Oral Rotavirus Vaccine Performance
|
||
Completed |
NCT02542462 -
Potential Mechanisms for Intussusception After Rotavirus Vaccine-Pilot Study
|
Phase 4 | |
Completed |
NCT00346892 -
To Evaluate 2 Doses of GSK Biologicals' Oral Live Attenuated Human HRV Vaccine Co-administered With Either OPV or IPV
|
Phase 2 | |
Not yet recruiting |
NCT05212935 -
A Surveillance Study on Timing and Coverage Of Rotavirus and MenB Vaccine Co-administration in Campania Region, Italy
|
||
Completed |
NCT00092456 -
Consistency Lots Vaccine Study (V260-009)
|
Phase 3 | |
Completed |
NCT00981669 -
Rotavirus Vaccine Produced by Butantan Institute
|
Phase 1 | |
Completed |
NCT05037435 -
Safety and Immunological Efficacy of the Pentavalent Rotavirus Vaccine - Rota-V-Aid™ (Live Attenuated Oral, Freeze-dried) at Healthy Adults Aged 18 to 45 Years.
|
Phase 3 | |
Completed |
NCT03483116 -
A Phase II Dose-ranging Study of Oral RV3-BB Rotavirus Vaccine
|
Phase 2 | |
Completed |
NCT03870061 -
Evaluation of an Infant Immunization Encouragement Program in Nigeria
|
N/A | |
Active, not recruiting |
NCT05621655 -
Safety and Immunogenicity Study of Recombinant Trivalent Rotavirus Subunit Vaccine in Healthy Infants and Toddlers
|
Phase 2 | |
Completed |
NCT00280111 -
Safety and Immunogenicity Study of Live Attenuated Indian Rotavirus Vaccine Candidate Strains 116E and I321 in Infants
|
Phase 1 | |
Completed |
NCT00090233 -
Rotavirus Efficacy and Safety Trial (REST)(V260-006)
|
Phase 3 |